First humans receive experimental antibody in early safety test
NCT ID NCT07248865
Summary
This is the first time a new antibody drug called CLYM116 is being tested in people. The main goal is to check if it is safe and how the body processes it. The study will involve up to 48 healthy volunteers who will receive injections of the drug or a placebo. Researchers will monitor for side effects and measure how long the drug stays in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network Brisbane
RECRUITINGBrisbane, 4006, Australia
Conditions
Explore the condition pages connected to this study.